The efficacy of adalimumab in the treatment of uveitis

Detalhes bibliográficos
Autor(a) principal: Oliveira , Liana Andrade
Data de Publicação: 2024
Outros Autores: Oliveira, Larissa Albuquerque, Barroso, Leticia Fernandes, Matos, Alexis Galeno
Tipo de documento: Artigo
Idioma: por
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/44915
Resumo: Uveitis is inflammation of the uveal tract. The main manifestations are ocular hyperemia, photophobia, ocular pain, blurred vision, irregular pupil and inflammatory nodules on the anterior surface of the iris. Currently, the treatment of uveitis is associated with the use of corticosteroids. Adalimumab (ADA) is a full-length human monoclonal antibody, which is involved in the intraocular inflammation cascade, being effective in suppressing uveitis, allowing a significant reduction in the immunosuppression burden and associated corticosteroid dosage. In this study, we performed a meta-analysis with the aim of evaluating the effectiveness of using ADA in the treatment of non-infectious intermediate and posterior uveitis and panuveitis. A systematic literature review study that addressed research published between 2016 and 2021. Our systematic review selected a total of 60 articles and, among these, 12 were used with different methodological approaches, with age groups and samples varied populations. Within our study, all 12 selected articles demonstrated, in general, a good efficacy and safety of biological therapy with ADA, mainly in combined therapy and aimed at the chronicity and refractoriness of the disease associated with evidence on a pattern of improvement in all or most of the outcomes assessed.
id UNIFEI_a6384c76f4dbdab4964ede89de331b18
oai_identifier_str oai:ojs.pkp.sfu.ca:article/44915
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling The efficacy of adalimumab in the treatment of uveitisLa eficacia de adalimumab en el tratamiento de la uveítisA eficácia do adalimumabe no tratamento da uveíte UveíteAdalimumabeCorticoideInflamação.UveítisAdalimumabCorticosteroidesInflamación. UveitisAdalimumabCorticosteroidsInflammation. Uveitis is inflammation of the uveal tract. The main manifestations are ocular hyperemia, photophobia, ocular pain, blurred vision, irregular pupil and inflammatory nodules on the anterior surface of the iris. Currently, the treatment of uveitis is associated with the use of corticosteroids. Adalimumab (ADA) is a full-length human monoclonal antibody, which is involved in the intraocular inflammation cascade, being effective in suppressing uveitis, allowing a significant reduction in the immunosuppression burden and associated corticosteroid dosage. In this study, we performed a meta-analysis with the aim of evaluating the effectiveness of using ADA in the treatment of non-infectious intermediate and posterior uveitis and panuveitis. A systematic literature review study that addressed research published between 2016 and 2021. Our systematic review selected a total of 60 articles and, among these, 12 were used with different methodological approaches, with age groups and samples varied populations. Within our study, all 12 selected articles demonstrated, in general, a good efficacy and safety of biological therapy with ADA, mainly in combined therapy and aimed at the chronicity and refractoriness of the disease associated with evidence on a pattern of improvement in all or most of the outcomes assessed.La uveítis es la inflamación del tracto uveal. Las principales manifestaciones son hiperemia ocular, fotofobia, dolor ocular, visión borrosa, pupila irregular y nódulos inflamatorios en la superficie anterior del iris. Actualmente, el tratamiento de la uveítis se asocia al uso de corticoides. Adalimumab (ADA) es un anticuerpo monoclonal humano de longitud completa, que participa en la cascada de inflamación intraocular, siendo eficaz en la supresión de la uveítis, permitiendo una reducción significativa de la carga de inmunosupresión y la dosis de corticosteroides asociada. En este estudio, realizamos un metanálisis con el objetivo de evaluar la efectividad del uso de ADA en el tratamiento de la uveítis y panuveítis intermedia y posterior no infecciosa. Estudio de revisión sistemática de la literatura que abordó investigaciones publicadas entre 2016 y 2021. Nuestra revisión sistemática seleccionó un total de 60 artículos y, entre estos, 12 fueron utilizados con diferentes enfoques metodológicos, con grupos de edad y muestras poblacionales variadas. Dentro de nuestro estudio, los 12 artículos seleccionados demostraron, en general, una buena eficacia y seguridad de la terapia biológica con ADA, principalmente en terapia combinada y dirigida a la cronicidad y refractariedad de la enfermedad asociada con evidencia de un patrón de mejoría en todos o la mayoría de los resultados evaluados.A uveíte é a inflamação do trato uveal. As principais manifestações são a hiperemia ocular, fotofobia, dor ocular, visão turva, pupila irregular e nódulos inflamatórios na superfície anterior da íris. Atualmente, o tratamento da uveíte é associado ao uso de corticosteroides. O Adalimumabe (ADA) é um anticorpo monoclonal humano de comprimento total, que está envolvido na cascata de inflamação intraocular, sendo eficaz na supressão de uveíte, permitindo uma redução significativa na carga de imunossupressão e na dosagem de corticosteroide associado. Neste estudo, realizamos uma meta-análise com o objetivo avaliar a eficácia do uso do ADA no tratamento da uveíte não-infecciosa intermediária, posterior e panuveítes. Um estudo de revisão sistemática da literatura que abordou pesquisas publicadas no período de 2016 a 2021. Nossa revisão sistemática, selecionou um total de 60 artigos e, dentre estes, foram utilizados 12 com diversas abordagens metodológicas, com faixas etárias e amostras populacionais variadas. Dentro do nosso estudo, todos os 12 artigos selecionados demonstraram, de maneira geral, uma boa eficácia e segurança da terapia biológica com o ADA, principalmente em terapia combinada e direcionado a cronicidade e refratariedade da doença associado a evidências em padrão de melhora de todos ou da maioria dos desfechos avaliados.Research, Society and Development2024-02-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/4491510.33448/rsd-v13i2.44915Research, Society and Development; Vol. 13 No. 2; e1713244915Research, Society and Development; Vol. 13 Núm. 2; e1713244915Research, Society and Development; v. 13 n. 2; e17132449152525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/44915/35895Copyright (c) 2024 Liana Andrade Oliveira ; Larissa Albuquerque Oliveira; Leticia Fernandes Barroso; Alexis Galeno Matoshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessOliveira , Liana Andrade Oliveira, Larissa Albuquerque Barroso, Leticia Fernandes Matos, Alexis Galeno 2024-03-04T09:47:20Zoai:ojs.pkp.sfu.ca:article/44915Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-03-04T09:47:20Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv The efficacy of adalimumab in the treatment of uveitis
La eficacia de adalimumab en el tratamiento de la uveítis
A eficácia do adalimumabe no tratamento da uveíte
title The efficacy of adalimumab in the treatment of uveitis
spellingShingle The efficacy of adalimumab in the treatment of uveitis
Oliveira , Liana Andrade
Uveíte
Adalimumabe
Corticoide
Inflamação.
Uveítis
Adalimumab
Corticosteroides
Inflamación.
Uveitis
Adalimumab
Corticosteroids
Inflammation.
title_short The efficacy of adalimumab in the treatment of uveitis
title_full The efficacy of adalimumab in the treatment of uveitis
title_fullStr The efficacy of adalimumab in the treatment of uveitis
title_full_unstemmed The efficacy of adalimumab in the treatment of uveitis
title_sort The efficacy of adalimumab in the treatment of uveitis
author Oliveira , Liana Andrade
author_facet Oliveira , Liana Andrade
Oliveira, Larissa Albuquerque
Barroso, Leticia Fernandes
Matos, Alexis Galeno
author_role author
author2 Oliveira, Larissa Albuquerque
Barroso, Leticia Fernandes
Matos, Alexis Galeno
author2_role author
author
author
dc.contributor.author.fl_str_mv Oliveira , Liana Andrade
Oliveira, Larissa Albuquerque
Barroso, Leticia Fernandes
Matos, Alexis Galeno
dc.subject.por.fl_str_mv Uveíte
Adalimumabe
Corticoide
Inflamação.
Uveítis
Adalimumab
Corticosteroides
Inflamación.
Uveitis
Adalimumab
Corticosteroids
Inflammation.
topic Uveíte
Adalimumabe
Corticoide
Inflamação.
Uveítis
Adalimumab
Corticosteroides
Inflamación.
Uveitis
Adalimumab
Corticosteroids
Inflammation.
description Uveitis is inflammation of the uveal tract. The main manifestations are ocular hyperemia, photophobia, ocular pain, blurred vision, irregular pupil and inflammatory nodules on the anterior surface of the iris. Currently, the treatment of uveitis is associated with the use of corticosteroids. Adalimumab (ADA) is a full-length human monoclonal antibody, which is involved in the intraocular inflammation cascade, being effective in suppressing uveitis, allowing a significant reduction in the immunosuppression burden and associated corticosteroid dosage. In this study, we performed a meta-analysis with the aim of evaluating the effectiveness of using ADA in the treatment of non-infectious intermediate and posterior uveitis and panuveitis. A systematic literature review study that addressed research published between 2016 and 2021. Our systematic review selected a total of 60 articles and, among these, 12 were used with different methodological approaches, with age groups and samples varied populations. Within our study, all 12 selected articles demonstrated, in general, a good efficacy and safety of biological therapy with ADA, mainly in combined therapy and aimed at the chronicity and refractoriness of the disease associated with evidence on a pattern of improvement in all or most of the outcomes assessed.
publishDate 2024
dc.date.none.fl_str_mv 2024-02-06
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/44915
10.33448/rsd-v13i2.44915
url https://rsdjournal.org/index.php/rsd/article/view/44915
identifier_str_mv 10.33448/rsd-v13i2.44915
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/44915/35895
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 13 No. 2; e1713244915
Research, Society and Development; Vol. 13 Núm. 2; e1713244915
Research, Society and Development; v. 13 n. 2; e1713244915
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052637437231104

Registros relacionados